Anuradha Budhu

National Institutes of Health — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

40h-index12.6kcitations158works5.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Lipids, and Metabolism(40), Cancer, Hypoxia, and Metabolism(28), Hepatocellular Carcinoma Treatment and Prognosis(24), Metabolomics and Mass Spectrometry Studies(24), Ferroptosis and cancer prognosis(24)

Publications158 total

Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer·2025Open Access
Urinary pesticide profiles and liver disease risk in Thailand: a machine-learning risk-prediction model
2025Open Access
Beneficial infections of the enterovirus genus in patients with liver cancer
Gut·2025
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
Immunity·2025· 18 cited
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Gut·2025· 14 citedOpen Access
NCI-CLARITY Retrospective Race associated study
Figshare·2025Open Access
NCI-CLARITY Retrospective Race associated study
Figshare·2025Open Access
Associations of chronic liver disease and liver cancer with glyphosate and its metabolites in Thailand
International Journal of Cancer·2024· 2 citedOpen Access
RWD144 Predictive Risk Score for Nonalcoholic Steatohepatitis (NASH) Among Patients in the Department of Defense Population
Value in Health·2024Open Access
The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand
International Journal of Cancer·2024· 13 citedOpen Access
Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma
Communications Biology·2024· 4 citedOpen Access
Lineage and ecology define liver tumor evolution in response to treatment
Cell Reports Medicine·2024· 8 citedOpen Access
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
Cancer Medicine·2024· 9 citedOpen Access
Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Cell Reports Medicine·2023· 13 citedOpen Access
Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing
Cell Reports·2023· 25 citedOpen Access
Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma
Scientific Reports·2023· 25 citedOpen Access
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy
Cell Reports Medicine·2023· 29 citedOpen Access
Abstract 6057: Association of liver cancer and chronic liver disease with urinary glyphosate and its metabolites in Thailand
Cancer Research·2023
Supplementary Table S6 from Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer
2023Open Access
Supplementary Data from MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Xin Wei Wang(45), Marshonna Forgues(26), Qing‐Hai Ye(13), Junfang Ji(11), Hu‐Liang Jia(10), Lun–Xiu Qin(10), Stéphanie Roessler(8), Tim F. Greten(8), Taro Yamashita(6), Zhao–You Tang(6), Snorri S. Thorgeirsson(6), Zhao–You Tang(6), Curtis C. Harris(6), Yidong Chen(5), Carlo M. Croce(5), Jittiporn Chaisaingmongkol(5), Lun‐Xiu Qin(4), Krista A. Zanetti(4), Stefan Ambs(4), Hien Dang(4)